Biostatistics in nonclinical and preclinical drug development

Biometrical Journal

Volumn 47, Issue 3, 2005, Pages 282-285

  Hothorn, L A ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT;

MEDICINE;

EID: 22144496501     PISSN: 03233847     EISSN: None     Source Type: Journal    
DOI: 10.1002/bimj.200510128     Document Type: Review

References (32)

1. Anonymous (2001). Guidance for industry. Statistical aspects of the design, analysis and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. PDA. (http://www.fda.gov/cder/guidance/815dft.pdf).
2. Bretz, F. and Hothorn, L. A. (2003). Statistical analysis of monotone or non-monotone dose-response data from in vitro toxicological assays. ATLA-Alternatives to Laboratory Animals 31, 81-96, Suppl. 1.
3. Chen, Y. Q., Pong, A., and Xing B. (2003). Rank regression in stability analysis. Journal of Biopharmaceutical Statistics 13, 463-479.
4. Conolly, R. B. and Lutz, W. K. (2004). Nonmonotonic dose-response relationships: mechanistic basis, kinetic modeling, and implications for risk assessment. Toxicological Sciences 77, 151-157.
5. Fang, H. B., Tian, G. L., and Tan, M. (2004). Hierarchical models for tumor xenograft experiments in drug development. Journal of Biopharmaceutical Statistics 14, 931-945.
6. Gaylor, D. W., Lutz, W. K., and Conolly, R. B. (2004). Statistical analysis of nonmonotonic dose-response relationships: research design and analysis of nasal cell proliferation in rats exposed to formaldehyde. Toxicological Sciences 77, 158-164.
7. Goumenou, M. and Machera, K. (2004). Mixture of paraquat and linuron formulations examined for genotoxicity in Wistar rats by the in vivo micronucleus test-evaluation by different statistical tests. Journal of Environmental Science Health B 39, 75-87.
8. Grouin, J. M. and Lewis, J. (2004). Committee for Proprietary Medicinal Products (CPMP): Points to consider on adjustment for baseline covariates. Statistics in Medicine 23, 2624.
9. Hauschke, D., Kieser, M., and Hothorn, L. A. (1999). Proof of safety in toxicology based on the ratio of two means for normally distributed data. Biometrical Journal 41, 295-304.
10. Hauschke, D., Hothorn, T., and Schafer, J. (2003). The role of control groups in mutagenicity studies: Matching biological and statistical relevance. ATLA-Alternatives to Laboratory Animals 31, 65-75, Suppl. 1.
11. Hauschke, D., Slacik-Erben, R., Hensen, S., and Kaufmann, R. (2005). Biostatistical assessment of mutagenicity studies including the positive control. Biometrical Journal 47, 82-87.
12. Hothorn, L. A. and Bretz, F. (2003). Dose-response and thresholds in mutagenicity studies: A statistical testing approach. ATLA-Alternatives to Laboratory Animals 31, 97-103, Suppl. 1.
13. Hothorn, L. A. and Bauss, F. (2004). Biostatistical design and analyses of long-term animal studies simulating human postmenopausal osteoporosis. Drug Information Journal 38, 47-56.
14. Han, K. E., Catalano, P. J., Senchaudhuri, P., and Mehta, C. (2004). Exact analysis of dose response for multiple correlated binary outcomes. Biometrics 60, 216-224.
15. Hauck, W. W. and Shaikh, R. (2004). Modified two-sided normal tolerance intervals for batch acceptance of dose uniformity. Pharmaceutical Statistics 3, 89-97.
16. Khatry, D. B. (2004). Statistical contributions in biotechnology and nonclinical drug-discovery research. American Statistician 58, 199.
17. Kiermeier, A., Jarrett, R. G., and Verbyla, A. P. (2004). A new approach to estimating shelf-life. Pharmaceutical Statistics 3, 3-11.
18. Lachenbruch, P. A., Rida, W., and Kou, J. (2004). Lot consistency as an equivalence problem. Journal of Biopharmaceutical Statistics 14, 275-290.
19. L'Heureux, P. J., Carreau, J., Bengio, Y. et al. (2004). Locally linear embedding for dimensionality reduction in QSAR. Journal of Computer-aided Molecular Design 18, 475-482.
20. Lee, S. (2003). Analysis of the Binary Littermate Data in the One-Way Layout. Biometrical Journal 45, 195-206.
21. Leighty, R. E., Nilsson, L. N., Potter, H., Costa, D. A., Low, M. A., Bales, K. R., Paul, S. M., and Arendash, G. W. (2004). Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behavioral Brain Research 153, 107-121.
22. Lendrem, D. (2002). Statistical support to non-clinical. Pharmaceutical Statistics 1, 71-73.
23. Le Chap, T. and Grambsch, P. M. (2005). Design and analysis of in vitro experiments for combination chemotherapy. Journal of Biopharmaceutical Statistics 15, 179-186.
24. Sand, S., von Rosen, D., Eriksson, P., Fredriksson, A., Viberg, H., Victorin, K. and Filipsson, A. F. (2004). Dose-response modeling and benchmark calculations from spontaneous behavior data on mice neonatally exposed to 2,2′,4,4′,5-pentabromodiphenyl ether. Toxicological Sciences 81, 491-501.
25. Stallard, N., Whitehead, A., and Indans, I. (2004). Statistical evaluation of an acute dermal toxicity test using the dermal fixed dose procedure. Human and Experimental Toxicology 23, 405-412.
26. Takeyoshi, M., Sawaki, M., Yamasakim, K., and Kimber, I. (2003). Assessment of statistic analysis in non-radioisotopic local lymph node assay (non-RI-LLNA) with alpha-hexylcinnamic aldehyde as an example. Toxicology 191, 259-263.
27. Tan, M., Fang, H. B., Tian, G. L. et al. (2003). Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Statistics in Medicine 22, 2091-2100.
28. Tan, M., Fang, H. B., Tian, G. L., and Houghton, P. J. (2005). Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Statistics in Medicine 24, 109-119.
29. Tye, H. (2004). Application of statistical 'design of experiments' methods in drug discovery. Drug Discovery Today 9, 485-491.
30. White, D. B., Faessel, H. M., Slocum, H. K. et al. (2004). Nonlinear response surface and mixture experiment methodologies applied to the study of synergism. Biometrical Journal 46, 56-71.
31. Wiklund, S. J. and Agurell, E. (2003). Aspects of design and statistical analysis in the Comet assay. Mutagenesis 18, 167-175.
32. Zhang, J. H., Chung, T. D. Y., and Oldenburg, K. R. (2000). Confirmation of primary active substances from high throughput screening of chemical and biological populations: A statistical approach and practical considerations. Journal of Combinatorial Chemistry 2, 258-265.